康芝药业(300086) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥174,602,090.13, representing a 58.81% increase compared to ¥109,945,844.25 in the same period last year[4] - Net profit attributable to shareholders was ¥15,414,673.27, a significant turnaround from a loss of ¥46,239,789.41, marking a 133.34% increase[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥13,669,875.91, up 127.64% from a loss of ¥49,455,947.08 in the previous year[4] - Basic earnings per share increased to ¥0.0343, compared to a loss of ¥0.1028 in the same period last year, reflecting a 133.37% improvement[4] - Diluted earnings per share also rose to ¥0.0343, a 133.37% increase from the previous year's loss of ¥0.1028[7] - The net profit for the period was ¥14,274,902.16, a turnaround from a net loss of ¥47,321,037.01 in the same period last year[23] - The total comprehensive income for the period was ¥14,274,902.16, contrasting with a comprehensive loss of ¥47,321,037.01 in the prior year[23] Cash Flow and Assets - The net cash flow from operating activities improved to -¥26,187,505.67, a 40.08% reduction in losses compared to -¥43,702,923.47 in the same period last year[4] - Cash inflow from operating activities totaled 146,784,213.28, compared to 143,161,131.71 in the previous period, reflecting a year-over-year increase of approximately 2.3%[26] - Cash outflow from operating activities decreased to 172,971,718.95 from 186,864,055.18, showing a reduction of about 7.4%[26] - The net cash flow from investing activities was 9,984,189.18, a significant improvement from -35,299,406.40 in the previous period[27] - The ending cash and cash equivalents balance was 179,523,081.44, an increase from 149,938,449.78 in the previous period[27] - The company’s cash and cash equivalents decreased by 90,288,259.66 during the period, compared to a decrease of 99,138,865.45 in the previous period[27] - Total assets at the end of the reporting period were ¥2,149,038,051.81, down 8.91% from ¥2,359,300,615.33 at the end of the previous year[4] - Total current assets decreased to ¥568.52 million from ¥670.46 million, reflecting a decline of about 15.2%[15] Liabilities and Equity - Total liabilities decreased from ¥932,963,148.62 to ¥779,254,536.87, a reduction of about 16.4%[19] - Shareholders' equity attributable to shareholders decreased to ¥1,331,597,779.09, an 8.65% decline from ¥1,457,709,429.86 at the end of the previous year[4] - The company's equity attributable to shareholders increased to ¥1,331,597,779.09 from ¥1,316,183,105.82, showing a growth of approximately 1.2%[19] Operational Highlights - The increase in revenue and profit was primarily driven by a significant rise in pharmaceutical sales due to market recovery[6] - The company reported a government subsidy of ¥2,145,400.82, which positively impacted the financial results[5] - The company successfully held a strategic seminar with China National Pharmaceutical Group, focusing on collaboration opportunities in the Hainan Free Trade Port[12] - The company was recognized as a "High-tech Enterprise" in Hebei Province, enhancing its credibility in technology research and development[13] - The company reported successful entry into a key technology research project for children's oral medication, indicating progress in R&D efforts[13] - The company signed a strategic cooperation agreement with International Universal (Indonesia) Group, aiming to expand its market presence[12] - The company plans to explore diversified cooperation channels and models for high-quality development with local government entities[13] Inventory and Receivables - Accounts receivable decreased to ¥50.09 million from ¥71.13 million, a reduction of about 29.5%[15] - Inventory increased significantly to ¥222.69 million, up from ¥170.40 million, marking an increase of approximately 30.6%[15] Research and Development - Research and development expenses were reported at ¥4,135,560.53, slightly down from ¥4,262,780.66, indicating a decrease of about 3.0%[21] Shareholder Actions - The company announced a shareholder reduction plan, with a significant portion of shares being reduced by over 1%[11]